{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:11:31Z","timestamp":1773256291884,"version":"3.50.1"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited comparative data exist on acute kidney injury (AKI) risk and AKI-associated outcomes in hospitalized patients with carbapenem-resistant Gram-negative infections (CR-GNIs) treated with a newer \u03b2-lactam\/\u03b2-lactam-\u03b2-lactamase inhibitor (BL\/BL-BLI)-, polymyxin (PB)- or aminoglycoside (AG)-containing regimen. This study quantified the risk of AKI and AKI-related outcomes among patients with CR-GNIs treated with a newer BL\/BL-BLI-, PB- or AG-containing regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre, retrospective, observational study was performed (2016\u201320). The study included adult hospitalized patients with (i) baseline estimated glomerular filtration rates \u226530 mL\/min\/1.73 m2; (ii) CR-GN pneumonia, complicated urinary tract infection or bloodstream infection; and (iii) receipt of newer BL\/BL-BLI, PG or AG within 7 days of index CR-GN culture for \u22653 days. Outcomes included AKI, in-hospital mortality and hospital costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 750 patients and most (48%) received a newer BL\/BL-BLI. The median (IQR) treatment duration was 8 (5\u201311), 5 (4\u20138) and 7 (4\u20138) days in the newer BL\/BL-BLI group, AG group and PB group, respectively. The PB group had the highest adjusted AKI incidence (95% CI) (PB: 25.1% (15.6%\u201334.6%) versus AG: 8.9% (5.7%\u201312.2%) versus newer BL\/BL-BLI: 11.9% (8.1%\u201315.7%); P = 0.001). Patients with AKI had significantly higher in-hospital mortality (AKI: 18.5% versus \u2018No AKI\u2019: 5.6%; P = 0.001) and mean hospital costs (AKI: $49 192 versus \u2018No AKI\u2019: $38,763; P = 0.043).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The AKI incidence was highest among PB patients and patients with AKI had worse outcomes. Healthcare systems should consider minimizing the use of antibiotics that augment AKI risk as a measure to improve outcomes in patients with CR-GNIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad351","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:19:50Z","timestamp":1699964390000},"page":"82-95","source":"Crossref","is-referenced-by-count":8,"title":["Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer \u03b2-lactam or \u03b2-lactam\/\u03b2-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences , Department of Pharmacy Practice, 106 New Scotland Avenue, Albany, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Yucel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engels N","family":"Obi","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre H","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , 2025 E Scott Ave, Rahway, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian H","family":"Nathanson","sequence":"additional","affiliation":[{"name":"OptiStatim LLC , 25 Willow Circle, Longmeadow, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"2024010416395978200_dkad351-B1","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2147\/IDR.S177247","article-title":"Health care-associated infections\u2014an overview","volume":"11","author":"Haque","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2024010416395978200_dkad351-B2","author":"Centers for Disease Control and Prevention (U.S.)","year":"2016"},{"key":"2024010416395978200_dkad351-B3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024010416395978200_dkad351-B4","author":"CDC","year":"2019"},{"key":"2024010416395978200_dkad351-B5","author":"CDC","year":"2013"},{"key":"2024010416395978200_dkad351-B6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024010416395978200_dkad351-B7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2024010416395978200_dkad351-B8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ajic.2014.02.013","article-title":"Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis","volume":"42","author":"Bogan","year":"2014","journal-title":"Am J Infect Control"},{"key":"2024010416395978200_dkad351-B9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis","volume":"17","author":"Zilberberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2024010416395978200_dkad351-B10","doi-asserted-by":"crossref","first-page":"ofz194","DOI":"10.1093\/ofid\/ofz194","article-title":"Antimicrobial resistance or delayed appropriate therapy\u2014does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenem-susceptible Enterobacteriaceae?","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024010416395978200_dkad351-B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","article-title":"Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious Gram-negative bacterial infections","volume":"357","author":"Bonine","year":"2019","journal-title":"Am J Med Sci"},{"key":"2024010416395978200_dkad351-B12","doi-asserted-by":"crossref","first-page":"ofy150","DOI":"10.1093\/ofid\/ofy150","article-title":"Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis","volume":"5","author":"Martin","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024010416395978200_dkad351-B13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2015.10.008","article-title":"Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"85","author":"Martirosov","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024010416395978200_dkad351-B14","author":"WHO"},{"key":"2024010416395978200_dkad351-B15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review","volume":"27","author":"Palacios-Baena","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024010416395978200_dkad351-B16","first-page":"1803","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B17","doi-asserted-by":"crossref","first-page":"16497","DOI":"10.1038\/s41598-021-95852-4","article-title":"Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia","volume":"11","author":"Lakbar","year":"2021","journal-title":"Sci Rep"},{"key":"2024010416395978200_dkad351-B18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"key":"2024010416395978200_dkad351-B19","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","article-title":"Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study","volume":"38","author":"Tabah","year":"2012","journal-title":"Intensive Care Med"},{"key":"2024010416395978200_dkad351-B20","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"2024010416395978200_dkad351-B21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"2024010416395978200_dkad351-B22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.hrtlng.2020.04.013","article-title":"Pre-existing chronic kidney disease and acute kidney injury among critically ill patients","volume":"49","author":"Abdalrahim","year":"2020","journal-title":"Heart Lung"},{"key":"2024010416395978200_dkad351-B23","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfm744","article-title":"A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients","volume":"23","author":"Bagshaw","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2024010416395978200_dkad351-B24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.2215\/CJN.04360514","article-title":"A prospective international multicenter study of AKI in the intensive care unit","volume":"10","author":"Bouchard","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010416395978200_dkad351-B25","doi-asserted-by":"crossref","first-page":"2173498","DOI":"10.1080\/0886022X.2023.2173498","article-title":"A new criteria for acute on preexisting kidney dysfunction in critically ill patients","volume":"45","author":"Hong","year":"2023","journal-title":"Ren Fail"},{"key":"2024010416395978200_dkad351-B26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"key":"2024010416395978200_dkad351-B27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41581-018-0052-0","article-title":"Global epidemiology and outcomes of acute kidney injury","volume":"14","author":"Hoste","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2024010416395978200_dkad351-B28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneph.2017.184","article-title":"Paradigms of acute kidney injury in the intensive care setting","volume":"14","author":"Kellum","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2024010416395978200_dkad351-B29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40620-013-0016-1","article-title":"Impact of preexisting chronic kidney disease on acute and long-term outcome of critically ill patients on a medical intensive care unit","volume":"27","author":"Lebiedz","year":"2014","journal-title":"J Nephrol"},{"key":"2024010416395978200_dkad351-B30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00134-021-06454-7","article-title":"Acute kidney injury in the critically ill: an updated review on pathophysiology and management","volume":"47","author":"Pickkers","year":"2021","journal-title":"Intensive Care Med"},{"key":"2024010416395978200_dkad351-B31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2011.339","article-title":"AKI In the ICU: definition, epidemiology, risk stratification, and outcomes","volume":"81","author":"Singbartl","year":"2012","journal-title":"Kidney Int"},{"key":"2024010416395978200_dkad351-B32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bja\/aes401","article-title":"Patients with end-stage renal disease admitted to the intensive care unit: systematic review","volume":"110","author":"Arulkumaran","year":"2013","journal-title":"Br J Anaesth"},{"key":"2024010416395978200_dkad351-B33","author":"CDC","year":"2019"},{"key":"2024010416395978200_dkad351-B34","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2024010416395978200_dkad351-B35","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2024010416395978200_dkad351-B36","doi-asserted-by":"crossref","first-page":"105328","DOI":"10.1016\/j.phrs.2020.105328","article-title":"Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury","volume":"163","author":"Sisay","year":"2021","journal-title":"Pharmacol Res"},{"key":"2024010416395978200_dkad351-B37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antibiotics8010024","article-title":"Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity","volume":"8","author":"Nation","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2024010416395978200_dkad351-B38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2024010416395978200_dkad351-B39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam versus polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B40","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jac\/dku561","article-title":"Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study","volume":"70","author":"Rigatto","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024010416395978200_dkad351-B41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","volume":"27","author":"Wagenlehner","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024010416395978200_dkad351-B42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2024010416395978200_dkad351-B43","doi-asserted-by":"crossref","first-page":"ofy191","DOI":"10.1093\/ofid\/ofy191","article-title":"The impact of acute kidney injury on the risk of mortality and health care utilization among patients treated with polymyxins for severe gram-negative infections","volume":"5","author":"Baradaran","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024010416395978200_dkad351-B44","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmi.2016.08.004","article-title":"Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections","volume":"22","author":"Durante-Mangoni","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024010416395978200_dkad351-B45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.06980717","article-title":"Attributable risk and time course of colistin-associated acute kidney injury","volume":"13","author":"Miano","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024010416395978200_dkad351-B46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40121-021-00556-x","article-title":"Utilization of colistin versus \u03b2-lactam and \u03b2-lactamase inhibitor agents in relation to acute kidney injury in patients with severe Gram-negative infections","volume":"11","author":"Doremus","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2024010416395978200_dkad351-B47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B48","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024010416395978200_dkad351-B50","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1473-3099(20)30153-5","article-title":"Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study","volume":"20","author":"Strich","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024010416395978200_dkad351-B51","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2024010416395978200_dkad351-B52","author":"PINC.","year":"2023"},{"key":"2024010416395978200_dkad351-B53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2024010416395978200_dkad351-B54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2024010416395978200_dkad351-B55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jeconom.2009.09.023","article-title":"Efficient semiparametric estimation of multi-valued treatment effects under ignorability","volume":"155","author":"Cattaneo","year":"2010","journal-title":"J Econom"},{"key":"2024010416395978200_dkad351-B56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024010416395978200_dkad351-B57","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"key":"2024010416395978200_dkad351-B58","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"2024010416395978200_dkad351-B59","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam versus colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024010416395978200_dkad351-B61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B62","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/AAC.02476-13","article-title":"In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy","volume":"58","author":"Phe","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024010416395978200_dkad351-B63","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/1471-2334-13-380","article-title":"Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study","volume":"13","author":"Sorli","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"Suppl 1","key":"2024010416395978200_dkad351-B64","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2105\/AJPH.2004.059204","article-title":"Causation and causal inference in epidemiology","volume":"95","author":"Rothman","year":"2005","journal-title":"Am J Public Health"},{"key":"2024010416395978200_dkad351-B65","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.02638-15","article-title":"Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae","volume":"60","author":"Shields","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024010416395978200_dkad351-B66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1086\/520991","article-title":"Back to the future: using aminoglycosides again and how to dose them optimally","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B67","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2024010416395978200_dkad351-B68","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2024010416395978200_dkad351-B69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s004670050386","article-title":"Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention","volume":"11","author":"Tune","year":"1997","journal-title":"Pediatr Nephrol"},{"key":"2024010416395978200_dkad351-B70","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12882-021-02503-x","article-title":"Risk factors, clinical features and outcome of new-onset acute kidney injury among critically ill patients: a database analysis based on prospective cohort study","volume":"22","author":"Jiang","year":"2021","journal-title":"BMC Nephrol"},{"key":"2024010416395978200_dkad351-B71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000322161","article-title":"RIFLE-based data collection\/management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit","volume":"31","author":"Garzotto","year":"2011","journal-title":"Blood Purif"},{"key":"2024010416395978200_dkad351-B72","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024010416395978200_dkad351-B74","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13054-016-1353-y","article-title":"Acute kidney injury: short-term and long-term effects","volume":"20","author":"Doyle","year":"2016","journal-title":"Crit Care"},{"key":"2024010416395978200_dkad351-B75","doi-asserted-by":"crossref","first-page":"7795096","DOI":"10.1155\/2021\/7795096","article-title":"Colistin-induced acute kidney injury and the effect on survival in patients with multidrug-resistant Gram-negative infections: significance of drug doses adjusted to ideal body weight","volume":"2021","author":"Arrayasillapatorn","year":"2021","journal-title":"Int J Nephrol"},{"key":"2024010416395978200_dkad351-B76","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024010416395978200_dkad351-B77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/cc11426","article-title":"Acute kidney injury and residual renal function","volume":"16","author":"Ronco","year":"2012","journal-title":"Crit Care"},{"key":"2024010416395978200_dkad351-B78","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"key":"2024010416395978200_dkad351-B79","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/CCM.0000000000000897","article-title":"Can we make performance measures more resilient to the effects of coding?","volume":"43","author":"Lagu","year":"2015","journal-title":"Crit Care Med"},{"key":"2024010416395978200_dkad351-B80","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/CCM.0000000000000862","article-title":"Gaming hospital-level pneumonia 30-day mortality and readmission measures by legitimate changes to diagnostic coding","volume":"43","author":"Sjoding","year":"2015","journal-title":"Crit Care Med"},{"key":"2024010416395978200_dkad351-B81","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M13-1419","article-title":"Variation in diagnostic coding of patients with pneumonia and its association with hospital risk-standardized mortality rates: a cross-sectional analysis","volume":"160","author":"Rothberg","year":"2014","journal-title":"Ann Intern Med"},{"key":"2024010416395978200_dkad351-B82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.00228-17","article-title":"Prevalence of invasive infections due to carbapenem-resistant Enterobacteriaceae among adult patients in US hospitals","volume":"61","author":"Lodise","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024010416395978200_dkad351-B83","doi-asserted-by":"crossref","first-page":"ofz446","DOI":"10.1093\/ofid\/ofz446","article-title":"Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection","volume":"6","author":"Carreno","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024010416395978200_dkad351-B84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MLR.0000000000001247","article-title":"Predicting the cost of health care services: a comparison of case-mix systems and comorbidity indices that use administrative data","volume":"58","author":"Huang","year":"2020","journal-title":"Med Care"},{"key":"2024010416395978200_dkad351-B85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MLR.0b013e31825f64d0","article-title":"Systematic review of comorbidity indices for administrative data","volume":"50","author":"Sharabiani","year":"2012","journal-title":"Med Care"},{"key":"2024010416395978200_dkad351-B86","doi-asserted-by":"crossref","first-page":"e020857","DOI":"10.1136\/bmjopen-2017-020857","article-title":"Validation of discharge diagnosis codes to identify serious infections among middle age and older adults","volume":"8","author":"Wiese","year":"2018","journal-title":"BMJ Open"},{"key":"2024010416395978200_dkad351-B87","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acr.21959","article-title":"Systematic review of validation studies of the use of administrative data to identify serious infections","volume":"65","author":"Barber","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024010416395978200_dkad351-B88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jclinepi.2006.07.011","article-title":"Veteran\u2019s affairs hospital discharge databases coded serious bacterial infections accurately","volume":"60","author":"Schneeweiss","year":"2007","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/1\/82\/55023710\/dkad351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/1\/82\/55023710\/dkad351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T17:57:57Z","timestamp":1704391077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/1\/82\/7420038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,14]]},"published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad351","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,14]]}}}